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ABSTRACT  
Background: The Breast Cancer Campaign Gap analysis (2013) established breast cancer research 
priorities without specific focus on surgical research nor the role of surgeons. The majority of breast 
cancer patients encounter a surgeon at diagnosis or during treatment, thus surgical involvement in 
design and delivery of high-quality research to improve patient care is critical.  This review aims to 
identify opportunities and priorities for breast surgical research to complement the previous gap 
analysis.      
Methods: Research-active breast surgeons met and identified topic areas for breast surgical 
research which mapped to the patient pathway.  These included diagnosis, neoadjuvant treatment, 
surgery, adjuvant therapy and special groups (e.g. risk-reducing surgery).  Section leads were 
identified based on research interests with invited input from experts in specific areas, supported by 
consultation with the Association of Breast Surgery (ABS) membership and Independent Cancer 
Patients’ Voice (ICPV). The document was iteratively modified until participants were satisfied that 
key priorities for surgical research were clear.  
Results: Key research gaps were identified for each topic area including: (1) issues surrounding 
overdiagnosis and treatment; (2) optimising selection for neoadjuvant therapies and subsequent 
surgery; (3) reducing re-operation rates for breast conserving surgery; (4) generating evidence for the 
clinical and cost-effectiveness of breast reconstruction and mechanisms for evaluating novel 
interventions; (5) determining optimal axillary management, especially post-neoadjuvant treatment; 
(6) defining and standardising indications for risk-reducing surgery.  Strategies for resolving these 
knowledge gaps are proposed.        
Conclusions: Surgeons are ideally placed for a central role in breast cancer research and should 
foster a culture of engagement and participation in research to benefit patients and the NHS. 
Development of infrastructure and surgical research capacity together with appropriate allocation of 
research funding will be needed to successfully address the key clinical and translational research 
gaps highlighted in this analysis within  the next two decades.  
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INTRODUCTION 
Breast cancer is the most common malignancy in the UK and the second commonest cancer 
worldwide1. More than 53,000 new cases are diagnosed annually in the UK, with one in eight women 
affected at some point in their lives2.  Breast cancer incidence continues to increase, and the disease 
constitutes a major public health issue with significant resource implications; estimates for healthcare 
costs per patient are in excess of £12,000 in the 15 months following diagnosis3.  Identifying cost-
effective treatments for breast cancer is therefore both a clinical and a research priority. Furthermore, 
significantly improved survival rates mean that long term post-surgical quality of life issues are 
increasingly important to patients. 
In 2012, the Breast Cancer Campaign (BCC) facilitated a series of workshops with the aim of identifying 
gaps in knowledge and formulating strategies to address these.  The resulting gap analysis4 prioritised 
areas for breast cancer research; however, there was minimal focus on surgical research or the 
potential role of surgeons in effective design and delivery of studies.  
Surgeons are uniquely placed for a pivotal role in breast cancer research.  Most patients see a surgeon 
at diagnosis and the majority undergo surgery as primary treatment.  Surgical engagement is crucial 
for identifying and recruiting patients to research at almost all stages of the treatment pathway.  
Involving surgeons in development of research strategies may optimise trial design, facilitate 
recruitment and ensure that trials successfully accrue to time and target. 
Historically, the pioneers in changing treatment paradigms for breast cancer were surgeons but 
nonetheless the quality of much surgical research has  been variable5. Less than 5% of all government 
healthcare research funding is currently spent on surgical projects6. The Royal College of Surgeons in 
the UK has recently invested in infrastructure to promote surgical research and secure additional 
funding7, aiming to improve quality and value of surgical research, enabling all surgeons to embrace 
research as a means of enhancing surgical practice and patient care.       
Surgical Gap Analysis 
4 
 
The Association of Breast Surgery (ABS) has recognised the need to increase engagement with breast 
cancer research. The ABS Academic and Research (A&R) Committee was convened in 2014 with the 
aim of “enhancing care and outcomes for patients with breast disease through the promotion and 
support of (surgical) research and innovation”. A key intention was to identify areas where surgeons 
could make significant research contributions, complementing the BCC gap analysis.  This paper 
outlines opportunities and priorities for breast surgical research highlighted by this exercise. 
METHODS 
The ABS A&R committee comprises research-active breast surgeons, trainees and patient 
representation. The committee agreed key topics on which to focus this surgical gap analysis and 
convened a workshop in May 2016. Chosen topics map to the patient care pathway and are listed as 
follows: a) diagnosis b) neoadjuvant therapy c) surgical treatment of the breast and axilla (including 
reconstructive and oncoplastic surgery) d) adjuvant therapy e) risk-reducing surgery and f) special 
groups (elderly, young women; breast cancer in pregnancy, male breast cancer and survivorship).  For 
the purpose of this review, “surgical research” was not confined to studies of surgical procedures or 
techniques; it also included areas relevant to surgical practice where surgeons could contribute to 
successful design, conduct and completion of breast cancer-related projects to complement the BCC 
gap analysis. 
Section leads were identified based on individual interests and expertise, had responsibility for enlisting 
further experts in each area and were tasked with providing a summary comment of:  
• existing knowledge 
• key surgical research questions in each area 
• proposed future research to address these gaps. 
The document was iteratively modified until all contributors considered that key themes and research 
priorities had been identified.  Consultation with ABS membership and Independent Cancer Patients’ 
Voice (ICPV) included presentation at the ABS Annual Conference in May 2017 and a survey, prior to 
preparation of the final document. 
Surgical Gap Analysis 
5 
 
The Gap Analysis survey was developed by members of the A&R Committee (RIC, SMcI, SP and 
MWR) based on key gaps identified by section leads and contributing experts (Appendix 1). 
Respondents were asked to rate the importance of research gaps in four areas (diagnosis and 
assessment (n=5); neoadjuvant therapy (n=7); surgical management (n=5) and special groups (n=5) 
on a 10-point Likert scale from 1 (not important) to 10 (most important) and to identify any additional 
research gaps that should be included in the analysis.  
The survey was circulated to the ABS membership by email and at conference and was open for six 
weeks between 15th May and 30th June 2017.  E-mail reminders were sent on two occasions to 
optimise response rates.  Survey Monkey software (www.surveymonkey.com) was used for data 
collection. 
All responses were summarised using simple summary statistics.  Thematic analysis of free-text was 
used to explore whether any key gaps had been omitted.  
RESULTS  
A provisional document for consultation including 22 proposed research gaps was developed with input 
from 35 research-active surgeons and invited experts (ABS Gap Analysis Working Group, appendix 2). 
The ABS Gap Analysis survey was completed by 40 additional ABS members, 98% (n=39) of whom 
felt that there were gaps in breast surgical research that would benefit from additional research.   All 22 
identified gapsreceived a median score of between 7 and 9 and so all were retained. No additional gaps 
were identified, although reference was made to some gaps discussed in the 2013 BCC analysis. 
Consistent with our stated aims these have not been reiterated here. The principal surgical gaps 
identified are summarised in Table 1 and discussed below. 
DIAGNOSIS AND ASSESSMENT 
Screen-detected breast cancer 
Approximately one third of breast cancer cases in England present through the National Health Service 
Breast Screening Programme (NHSBSP)2 and addressing overdiagnosis (defined as detection of 
cancers that would never have been found were it not for the screening test) and overtreatment of 
Surgical Gap Analysis 
6 
 
screen-detected breast cancer has been identified as a research priority in a recent independent 
review8. 
Addressing overtreatment 
Surgeons have a key role in screening studies as traditionally they have been responsible for excision 
of screen-detected lesions.  Use of vacuum-assisted biopsy (VAB) to obtain larger samples for 
histological assessment has replaced excision biopsy for many women with ‘B3’ lesions (of uncertain 
malignant potential)9 but lack of randomised evidence has prevented universal uptake of the technique. 
The natural history of some B3 lesions (e.g. lobular carcinoma in situ (LCIS), flat epithelial atypia (FEA), 
and atypical ductal hyperplasia [ADH]) remains uncertain, and RCTs are required to determine the 
optimal management of indeterminate lesions. 
Whilst there is agreement (albeit without supporting randomised evidence) that high-grade ductal 
carcinoma in situ (DCIS) requires surgical intervention, there is more uncertainty regarding 
management of low and intermediate grade DCIS10.  LORIS (Low Risk DCIS) is a phase III trial 
comparing active monitoring with surgery for patients with screen-detected low risk DCIS, with the 
primary end-point being development of ipsilateral invasive breast cancer. The non-inferiority design 
aims to demonstrate whether active monitoring is not inferior to standard surgery in this group of 
women11.  Similar studies are underway worldwide12 13, and translational studies to identify candidate 
biomarkers of disease progression are integral to these trials. 
Symptomatic breast cancer 
Streamlining referral and diagnostic pathways for symptomatic breast patients 
Over half of breast cancers are diagnosed in symptomatic clinics following triple assessment14-16 
although over 90% of patients presenting to symptomatic breast clinics do not have cancer17. Alternative 
assessment methods, including radiology-led triple-assessment services or primary care open access 
schemes, may be more cost-effective than the current model, but require robust evaluation to 
demonstrate acceptable sensitivity, specificity and reliability before introduction. 
Advanced and emerging breast imaging modalities  
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Research is needed to establish the role of breast magnetic resonance imaging (MRI) for specific 
scenarios such as assessing operability, clarifying local extent and planning complex breast conserving 
surgery18, as well as determining which patient groups may benefit from imaging with novel modalities 
such as contrast-enhanced mammography and digital breast tomosynthesis19. More sophisticated 
imaging may result in increased detection of previously subclinical ipsi- and contralateral breast lesions, 
mandating further radiological and pathological evaluation and potential excision20. There is a need to 
elucidate the clinical/biological significance of such lesions, and the impact of occult 
multifocality/multicentricity on oncological outcomes, to determine whether such small, previously 
subclinical lesions require surgical intervention. Furthermore, the impact of detecting and investigating 
subclinical disease on psychological well-being of women warrants further investigation. 
Staging investigations 
Staging investigations for distant metastases are not routinely recommended for asymptomatic patients 
presenting with breast cancer.  Current practice is variable21 and treatment decision making when 
lesions of uncertain clinical significance are identified can be challenging. Studies are needed to 
determine the most appropriate strategies and imaging modalities for staging and monitoring equivocal 
lesions. 
MANAGEMENT  
Management of breast cancer is multimodal and the BCC gap analysis4 recognises the need for a more 
personalised approach. Several areas of controversy relate to optimal selection and sequencing of 
treatment strategies in the neoadjuvant setting, including tailoring and sequencing local therapies 
(surgery and radiotherapy) after primary systemic therapy, and the potential role and outcomes of 
response-adapted surgery. 
Neoadjuvant therapy 
Neoadjuvant therapy is an established option in management of  locally advanced breast cancer22, and 
can downsize larger cancers, permitting breast conservation. Neoadjuvant chemotherapy (NAC) is as 
effective as adjuvant chemotherapy in terms of overall survival for patients with operable cancer23-26.  It 
allows disease down-staging, thereby potentially reducing the extent of surgery, although this may be 
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associated with increased rates of local recurrence, the reasons for which are unclear and warrant 
further investigation23. Neoadjuvant endocrine therapy (NET) is an alternative to NAC in women with 
oestrogen receptor positive (ER+) breast cancer, and further work is needed to establish the optimal 
duration of treatment27. Combination therapies (e.g. CDK4/6 inhibitors with aromatase inhibitors) may 
increase response rates,and are currently being explored in ongoing studies. There is less randomised 
evidence to support NET than for NAC in terms of impact on long-term survival. Of note, the POETIC 
trial demonstrated that response to short-term pre-operative aromatase inhibitor therapy did not impact 
time to recurrence28. 
Identifying patients who may benefit from neoadjuvant therapy 
Benefits of NAC in certain disease subgroups are well-established, with pCR rates of up to 50% seen 
in triple negative breast cancer with some regimens29. In HER2-positive disease, dual targeting with 
anti-HER2 therapies combined with chemotherapy can further increase pCR rates30,31. A meta-analysis 
did not confirm pCR to be a surrogate for improved overall survival32, although pCR at an individual 
patient level was prognostic. However, improved ability to identify patients likely to respond favourably 
to neoadjuvant therapies remains a key research focus and will guide clinical decision-making on 
sequencing of chemotherapy and surgery. 
The optimal selection of neoadjuvant therapy (NAC or NET) in post-menopausal patients with ER 
positive disease remains to be determined.  The role of molecular assays has yet to be fully elucidated33 
although early results with the 21 gene assay suggest possible clinical utility34. Likewise, a 4-gene 
signature has recently been proposed to allow patients to be classed as likely long-term responders or 
non-responders within 2 weeks of starting endocrine therapy35. Further high-quality prospective 
evidence is necessary to determine the value of such biomarkers. 
Monitoring response to neoadjuvant therapy 
Response can be assessed either clinically or radiologically and improved techniques for detection of 
early response may permit treatment strategies to be adjusted in non-responders (e.g. change of 
neoadjuvant regimen or proceed to surgery)36. Accurate prediction of response may increase the 
reliability of surgical decision-making when evaluating potential down-staging for breast conservation. 
Techniques to optimise monitoring of response may include novel imaging modalities, e.g. drug-induced 
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apoptosis has been described as a possible functional imaging technique in this context37. Further 
validation will however be required before such approaches can be utilised in the clinical setting. 
Management of patients with a complete pathological response in the breast 
The necessity for surgery in patients achieving pCR following neoadjuvant treatment remains to be 
addressed, and robust minimally-invasive methods to confirm pCR prior to surgery are needed.      The 
NOSTRA trial aims to address this question by examining the need for surgery in HER-2 positive 
patients achieving pCR following combination NAC and dual anti-HER-2 therapy. In the feasibility phase 
all patients will undergo surgery, to determine whether patients with a pCR can be identified pre-
operatively with multiple ultrasound-directed tumour-bed biopsies.  In the main trial, patients with 
apparent pCR will be randomised to either surgery and radiotherapy or radiotherapy alone. This trial 
may demonstrate that surgery can be safely omitted in selected patients where the absence of residual 
disease can be accurately and reliably identified. Long-term follow-up will clearly be essential to monitor 
outcomes. Similar studies are ongoing internationally to address this question38. 
Management of the axilla in patients undergoing neoadjuvant chemotherapy 
Two key questions remain to be resolved in management of the axilla in the context of NAC: the timing 
of SLNB in patients clinically and radiologically node-negative at diagnosis, and the surgical 
management of patients who are initially biopsy-proven node-positive, but apparently convert to node-
negative status following NAC. 
In patients node-negative at presentation, current options are SLNB pre-treatment, or following NAC. 
Upfront SLNB potentially overtreats patients with subclinical nodal involvement which may be 
downstaged by NAC, as positive pre-treatment SLNB usually commits a patient to additional axillary 
treatment (surgery or radiotherapy). Between 40%-75% of patients with axillary metastasis at diagnosis 
become node negative following NAC, raising the possibility of post-treatment SLNB in this group.  Two 
prospective cohort studies39,40 have demonstrated high false negative rates in this setting.  The 
sensitivity of SLNB was acceptable when post-treatment, nodes reverted to normal morphology on 
ultrasound, dual localisation techniques were used and a minimum of 3 nodes retrieved.  The use of 
pre-treatment techniques for marking positive axillary lymph nodes prior to neoadjuvant therapy may 
improve accuracy by allowing targeted axillary dissection in this setting. This has been described using 
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a variety of methods including radioactive iodine seeds and clipping  of positive node(s) 41-43 but these 
approaches require further evaluation and the question remains whether SLNB alone is safe in this 
setting, where there is potential risk of residual chemo-resistant axillary disease 
With respect to neoadjuvant treatments, in the first instance, improved data are required to understand 
real world rates of conversion to breast conservation, change of chemotherapy regimen due to non-
response, early abandonment of NAC in favour of early surgery, pCR rates, long-term local recurrence 
rates and overall survival. 
Window of opportunity studies 
Window of opportunity (WoO) studies utilise the short time interval between diagnosis and surgery to 
examine biological effects of novel treatments in the in vivo setting. Window studies can: 
a) demonstrate, confirm or validate (proposed) biological mechanism(s) of action 
b) identify resistance or sensitivity profiles pre- and post- treatment 
c) identify surrogate endpoints that may correlate with long-term outcomes (such as changes in specific 
biomarkers seen in biopsies at diagnosis and at surgery)  
They require a fraction of the time, cost and patient exposure to test therapies, compared with adjuvant 
trials.  The “post-neoadjuvant window” between completion of neoadjuvant chemotherapy and surgery 
in those patients who fail to respond completely to treatment represents a further novel therapeutic 
opportunity which has yet to be exploited.  Repeat tumour biopsy at conclusion of treatment can be 
used to identify patients with residual disease who might be suitable for targeted therapies during this 
timeframe. 
WoO studies may provide an evidence base for proceeding to phase III trials. Surgeons have a role in 
the design and delivery of such trials. Involving patient advocates is also vital to allow concerns 
surrounding the acceptability of such studies to be addressed.  Examples include reassurance to 
research ethics committees regarding tissue collection pre-treatment and open discussion of the effects 
of trial participation on scheduling of surgery. For practical purposes, trial entry counts as treatment for 
the purposes of meeting health service waiting time targets44. 
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Surgery for breast cancer 
Surgery to the breast 
Strategies to improve breast conserving surgery and to reduce re-excision rates 
Surgical resection margins remain contentious, but there is broad consensus that a negative margin, 
regardless of extent, is key to reducing local recurrence for invasive disease45. Currently, one in five 
women require further excision because of involved resection margins46. This represents a significant 
burden for patients and healthcare providers, and strategies to reduce margin positivity are a research 
and clinical priority. 
Intra-operative margin assessment 
Technologies allowing intra-operative margin assessment offer further potential to reduce re-excision 
rates beyond routine specimen radiology47. Intra-operative margin assessment techniques including 
imprint cytology and frozen section have not become routine practice due to resource limitations48. 
Emerging technologies for margin assessment potentially offer rapid and reliable methods for reducing 
rates of margin positivity. These include the MarginProbe (radiofrequency reflection)49, ClearEdge50 
(bio-impedance spectroscopy), and LightPath (Cerenkov Luminescence Imaging51). Other technologies 
such as Raman Spectroscopy52 and the iKnife Rapid Evaporative Ionisation Mass Spectrometry 
technology53 are also being explored, Feasibility and validation studies are required for all these 
technologies to determine clinical utility and cost-effectiveness. Surgeon-led multi-centre trials are 
necessary for comparison of newer technologies with current margin assessment techniques. This in 
turn will determine relative impact on re-excision rates. 
Tumour localisation for non-palpable lesions 
The ideal localisation method should be safe, accurate, deliverable in advance of the planned operation 
date and cost-effective. New approaches to localisation include use of radioactive54 and magnetic 
seeds55. These may offer benefits over standard wire-guided techniques and are being validated in on-
going studies with promising early results56,57. However, magnetic seeds limit subsequent use of MRI 
for imaging unless completely removed, and further evaluation is essential before comparative studies 
can be undertaken. 
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Surgeons have clear responsibilities in trialling new devices and participating in adequately powered 
prospective collaborative studies to validate novel localisation techniques. The current European 
approach to device testing involves CE marking of the device with no regulatory requirement for post-
market research. A coordinated approach mandating prospective data collection (post-CE marking) for 
new devices is necessary,and working closely with the Medicines and Healthcare products Regulatory 
Agency (MHRA) and equivalent international bodies to ensure more robust assessment and evaluation 
may be one way to achieve this. 
Alternatives to surgical excision 
Standard surgical excision may be unnecessary for small, low-grade screen-detected cancers for which 
percutaneous ablation techniques such as cryotherapy, radiofrequency ablation, high-intensity focused 
ultrasound and laser therapy may be appropriate.  However, techniques that completely ablate 
cancers58,59 raise concerns about margin assessment and definitive histopathology. Hence 
percutaneous excisional techniques to remove tumours may be preferable in this respect. Further 
research will clarify which cancers are amenable to treatment with minimally-invasive techniques60-62, 
who requires adjuvant radiotherapy, and what constitutes adequate axillary management for individual 
patients. 
Appropriate end-points for de-escalation studies need to be clearly defined and include local or regional 
recurrence, disease-free and overall survival. Designing studies which provide definitive data may pose 
significant methodological challenges. Randomised controlled studies with non-inferiority design are 
the gold standard but may be challenging due to patient and clinician preferences in non-blinded 
studies. Large cohort or patient preference studies may be more acceptable in this context. 
Multidisciplinary working, alongside patient advocates, will be necessary to define appropriate end-
points and deliver well-designed studies that address these key questions. 
 
Adjuvant radiotherapy  
Adjuvant radiotherapy is an integral part of loco-regional therapy and reduces local recurrence.  Intra-
operative radiotherapy may safely reduce the burden of treatment on the patient and enable more 
Surgical Gap Analysis 
13 
 
accurate targeting of tissues at risk101 and the ongoing TARGIT-B trial will provide further data on 
potential benefits of this approach in terms of local tumour control and adverse effects. Avoidance of 
radiotherapy may be possible in some patient groups, particularly in light of the findings of the CALGB 
9343 trial, which has confirmed low rates of ipsilateral recurrence at 10 years in patients ≥ 70 years of 
age with hormone receptor positive node negative tumours under 5cm treated with adjuvant hormone 
therapy alone after wide local excision63. This question is being addressed by the ongoing PRIMETIME 
study64. 
Breast reconstruction and oncoplastic surgery 
Breast reconstruction is offered to improve cosmesis, body image and quality of life for women 
undergoing mastectomy65. Many reconstructive options are available, from implant-based techniques 
to autologous procedures. These can be performed at mastectomy or a later date. Decision-making for 
breast reconstruction can be complex, with reports of dissatisfaction and regret not uncommon66,67. 
Decision aids may reduce decisional conflict and increase knowledge about options68 but these must 
be based on high-quality evidence. 
High-quality patient-centred short and long-term outcome data for different reconstructive techniques 
are currently lacking69,70.Inconsistent and heterogeneous reporting of outcomes precludes comparison 
of results from different studies and there is an urgent need for a robust set of standardised 
outcomes, allowing comparisons across studies. Therefore, a core outcome set has been 
developed71, which includes 11 clinical, patient-reported and cosmetic outcomes important to both 
patients and healthcare professionals. Agreement regarding how to measure these outcomes is 
important before effective integration into research and clinical implementation. Development of a 
simple, reliable and valid method for assessing cosmetic outcomes of breast reconstruction is 
ongoing and includes use of three-dimensional imaging techniques72. Furthermore, inclusion of 
patient reported outcomes should be standard in all future research and well-validated tools are 
required for this purpose. One such tool is the BREAST-Q 73,74, which is comprehensive, includes 
domains for breast satisfaction together with psychosocial and sexual well-being and is finding 
universal application. 
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The incidence of multifocal and multicentric cancers has increased with MRI usage and screening. 
Despite limitations of studies addressing surgical treatment of multiple ipsilateral breast cancers, rates 
of local recurrence are low after oncoplastic breast conserving surgery with no survival detriment. This 
has prompted the first randomised trial evaluating therapeutic mammaplasty versus standard 
mastectomy for these cases75.  
With broadening indications for postmastectomy radiotherapy76 (PMRT), further research is required to 
determine how to integrate radiotherapy into management plans to minimize surgical complications and 
adverse cosmetic outcomes in breast reconstruction77,78. A well-designed randomised trial addressing 
this issue has previously failed to recruit79 however a recent survey of European practice confirms that 
there remain controversies around the scheduling of PMRT in the context of reconstructive surgery80. 
This question will be in part addressed by the PRADA trial 
(https://clinicaltrials.gov/ct2/show/NCT02771938), which is a non-randomised phase II trial exploring 
whether radiotherapy before mastectomy and autologous breast reconstruction is associated with 
improved aesthetic results without increasing post-operative complications secondary to upfront 
radiotherapy. Data from this study is awaited,  although further research is  required to resolve these 
issues and non-randomised studies with standardised outcome measures may be a pragmatic 
wayforward.   
The optimal approach to implant-based breast reconstruction is another area of controversy.  This is a 
rapidly evolving area and it is unclear what type of biological or synthetic mesh should be used and 
whether implants should be placed in the subpectoral or pre-pectoral plane. RCTs are challenging but 
the iBRA (implant Breast Reconstruction evAluation) study81 (ISRCTN37664281) has prospectively 
recruited over 2000 patients undergoing new approaches to implant-based reconstruction at 81 centres 
to inform the feasibility and design of a future trial.     
New surgical techniques must be prospectively evaluated using robust methodology.  There should be 
“no innovation without evaluation” and infrastructure should be in place to support the introduction of 
new procedures and devices in a controlled and monitored fashion, encouraging more efficient 
innovation whilst protecting patients. The IDEAL framework82 provides a methodology for achieving 
this. Adoption of innovation can be improved by collaborative approaches, linked to a network of high-
volume centres willing and able to evaluate new devices and techniques.  Engagement of industry and 
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regulators, as well as surgeons, in post-market surveillance of medical devices will be essential to 
deliver these innovation programmes in a timely and cost-effective fashion. Some aspects of best 
practice for devices and implants may be developed from regulatory processes for new medicinal 
products. Furthermore, in order to embed best practice in the context of complex procedures such as 
implant-based breast reconstruction, an improved understanding of the nature of adoption and 
implementation of such practice is necessary. 
Management of the axilla 
Management of the axilla has become increasingly conservative and high-quality imaging may in future 
replace SLNB in patients with low-risk cancers. The SOUND trial (Sentinel node versus Observation 
after axillary UltraSouND)83 aims to address this, and recent work suggests this approach may be safe 
in selected patients84. In addition, with increasing numbers of patients having SLNB, the feasibility of 
repeat SLNB in patients with local recurrence and optimal management of the axilla following isolated 
regional nodal recurrence needs to be addressed. 
Patients with low volume nodal disease found by sentinel node biopsy 
There is continued controversy over treatment of sentinel node macrometastases. ACOSOG Z0011 
challenged the therapeutic benefit of ANC for this patient group. However, these findings have not been 
readily adopted into clinical practice in the U.K. This may in part be due to the fact that Z0011 did not 
include mastectomy patients, and that half of patients received high tangent radiotherapy fields which 
may have favoured equivalence of outcomes. Recent updated analysis at 10 years85, confirming no 
significant difference in recurrence or survival, may go some way to addressing these concerns. The 
POSNOC trial86 is exploring management of sentinel node macrometastases in both BCS and 
mastectomy patients, and will accrue 1900 patients, potentially providing more definitive answers on 
the safety of SLNB alone for patients with sentinel node macrometastases receiving adjuvant systemic 
therapies. Finally, the benefit of axillary dissection in patients with a clinically negative but needle biopsy 
positive axilla remains to be elucidated – these patients are eligible for entry into POSNOC and this 
may provide data to guide the management of this patient group. 
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Further advances in imaging technologies, percutaneous sampling techniques and systemic therapies 
for breast cancer may be forthcoming, and there is potential for elimination of surgical staging of the 
axilla in selected patients with node-negative and possibly some cases of node-positive disease. 
 
SPECIAL GROUPS 
Patients at high risk 
Risk-reducing surgery 
Management of women with a strong family history but no identified genetic mutation 
The surgical management of high-risk women with germline BRCA mutations is well-established, with 
bilateral risk-reducing mastectomy achieving a significant reduction (>90%) in breast cancer 
incidence87, although survival benefit remains unproven88. The optimal management of women with a 
strong family history of breast cancer but no identifiable mutation in a predisposition gene remains 
unclear, with no consensus about when (or if) risk-reducing surgery should be offered. Surgical 
intervention is not without risk and may include adverse psychosocial sequelae, decisional regret and 
dissatisfaction89. Well-designed studies using validated instruments for patient reported outcomes are 
lacking.  Surgeons are often approached directly about risk-reducing surgery and are ideally placed to 
explore these issues alongside patients and psychologists. 
Contralateral prophylactic mastectomy 
Rates of contralateral prophylactic mastectomy (CPM) are increasing and more patients with unilateral 
breast cancer are requesting contralateral surgery with or without reconstruction either at initial 
diagnosis or subsequently90.  There is no clear evidence for survival benefit for CPM91 in the absence 
of a genetic predisposition. Despite recent guidelines92, there is no consensus for optimal management 
of this group93-95. There is a need to explore relative benefits and harms of CPM with accurate reporting 
of complications, long-term sequelae and validated patient-reported outcomes. Work to improve the 
effective communication of the competing risks (recurrence from the index primary and development of 
a new primary) will also be important to help with these complex decision-making processes and allow 
women to make fully informed choices. 
    
Surgery for metastatic disease 
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A randomised trial96 found no survival benefit from excision of the primary tumour in patients with 
metastatic disease.  In the context of improved systemic and biological therapy for certain tumour 
subgroups, however, further research is required to identify specific patient subgroups which may 
benefit from excision of the primary tumour (such as those with isolated bone metastases97 or with 
complete resolution of distant disease), and how this might impact on quality of life. 
Further work is also needed to establish the magnitude of survival benefit from resection of breast 
cancer metastases. Non-randomised studies suggest that in selected patients, resection may be 
associated with significant survival benefit98,99 but RCTs are needed to definitively establish the value 
of this approach. Other treatment modalities including stereotactic radiotherapy, radioablation and 
cryoablation of metastatic lesions require robust clinical evaluation.  
Surgery for lymphoedema 
Lymphoedema following axillary surgery is disabling and adversely impacts quality of life.  Surgery such 
as lymphaticovenous anastomosis and vascularised lymph node transfer may significantly improve 
outcomes for patients with severe symptoms100 but further research is required to evaluate both the 
safety and effectiveness of these techniques and determine which patients derive symptom benefit 
while minimising donor site morbidity101.    
Young women 
Management of breast cancer in young women presents specific challenges and multidisciplinary 
guidelines for optimal management of this group have recently been published102.  Data from the 
POSH103 cohort study have shown that in the absence of a known pathogenic germline mutation, there 
is no survival advantage from mastectomy compared with BCS.  
Research is required to explore how concerns specific to young women should be managed.  These 
include issues relating to fertility, bone health, consequences of extended endocrine therapy, and the 
psychological impact of a breast cancer diagnosis not only on the patient, but also their partners and 
family. Indications for germline mutation testing remain to be defined and the probability threshold for 
testing in the UK has recently been decreased from 20% to 10%.  The surgeon has an important role 
in engaging with clinical geneticists and other collaborators to answer these key questions. 
Pregnancy associated breast cancer 
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Pregnancy–associated breast cancer (PABC) is estimated to affect 2.4-7.8 women per 100,000 live 
births.  Two large on-going studies in the UK and Europe104 105 will explore the incidence and short-term 
outcomes of PABC. Surgeons working in collaboration with obstetricians are ideally placed to recruit 
patients to relevant studies. 
Older women 
The management of women with breast cancer diagnosed over the age of 70 years varies widely across 
the UK106-108, and is currently the subject of a national audit51. Older patients are more likely to be 
managed with primary endocrine therapy without surgery.  Although several randomised trials have 
shown overall survival to be similar to combined surgery and adjuvant endocrine therapy, a  Cochrane 
Review revealed that local control was significantly worse in the absence of surgical treatment109. 
Furthermore, those offered surgery are more likely to undergo mastectomy without the potential benefit 
of downstaging from neoadjuvant therapies and axillary management is more likely to be non-guideline 
compliant in older patients. 
Whilst adjuvant chemotherapy is widely employed in younger women, usage is more selective and 
variable in patients over 70 years110.  Failure to include older patients in clinical trials and tendencies to 
overestimate comorbidity and frailty whilst underestimating therapeutic benefit collectively influence 
treatment recommendations in the older patient. 
Randomised trials to address these questions have failed to recruit for several reasons including lack 
of equipoise on the part of both clinician and patient111. However, both cohort112 and qualitative 
studies113 investigating factors which influence patient choice and evaluate interventions to reduce 
treatment variation have been more successful. 
Male breast cancer 
Male breast cancer represents 0.5–1% of all breast cancers and has been understudied, with 
management decisions often extrapolated from studies of female breast cancer.  This may be 
inappropriate as recent evidence suggests that these cancers may be biologically different.  The 
majority of men with breast cancer will undergo primary surgery, and surgeons have a central role in 
recruiting these patients to on-going studies and promoting tissue collection for research. 
RESEARCH METHODOLOGY 
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Multidisciplinary collaboration 
Clinical research is multidisciplinary based and continued collaboration between   breast surgeons and 
other disciplines is essential for ensuring advances in breast cancer researchacross the globe. 
Surgeons play roles as research leaders within their own areas of expertise, and are vital as 
collaborators within research teams. There is clear evidence of a changing culture and attitude in breast 
surgery in the UK with annual ABS Multidisciplinary Meetings bringing together experts to debate 
controversial topics and an increasingly visible surgical presence within national multidisciplinary 
research infrastructure such as the  National Cancer Research Institute (NCRI) Breast Clinical Studies 
Group and the UK Breast Intergroup creating an environment where such collaborations can flourish.  
Consolidating and building on these successes will be crucialto increase research capacity and facilitate  
delivery of well-designed research to address gaps highlighted in this review.   
Patient and public involvement 
Patient and public involvement is central to the delivery of high-quality research and patients are key to 
any successful multidisciplinary collaboration.  Patients should be involved in the design, development 
and delivery of studies to ensure that research is relevant and addresses questions with clear patient 
focussed outcomes.  Shared decision making approaches to breast cancer treatment should be 
explored in clinical trials With inclusion of patient reported outcomes as standard. Breast cancer 
survivorship and secondary prevention are discussed in detail in the BCC gap analysis4. As surgeons 
have a significant role in the follow-up and ongoing management of patients with breast cancer they 
are well placed to work with patients to deliver research in these areas. 
Clinical research 
The surgeon is well placed to synthesise current evidence, formulate new hypotheses, identify and 
question inconsistencies in current approaches, and to help design and develop innovative clinical trials. 
The surgeon is central to patient recruitment, monitoring and sample collection and represents a key 
link between patient and translational scientist. Surgeons are responsible for the diagnostic process 
and are involved in treatment planning for most breast cancer patients, and thus are key to recruitment 
to biological studies in the perioperative period which are increasingly important in the development of 
stratified medicine. Surgeons are usually trusted for advice and information and need to be enthusiastic 
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advocates of clinical trials; ensuring patients have full and equal access to information and participation 
in clinical research studies. 
Although well-designed, pragmatic randomised trials are considered the ‘gold standard’ for determining 
efficacy, they may not be possible in some areas including assessment of radiotherapy effects on breast 
reconstruction, risk-reducing surgery or in certain groups such as older patients.  In these settings, 
prospective cohort studies may be a reasonable alternative with rapid creation of large and powerful 
datasets which allow hypotheses to be explored and key questions addressed.  The trainee research 
collaborative model has emerged as a successful cost-effective way of conducting these types of 
studies. Engaging trainees also has the potential to augment research capacity by fostering a new 
generation of surgeons with an understanding of research methodology, patient and public involvement 
and engagement in trial recruitment114-116. The success of this approach has recently been evidenced 
by a trainee-delivered prospective audit evaluating current practice with respect to resection margins117. 
Collaboration with psychosocial and qualitative researchers may allow surgeons to develop studies to 
explore issues around topics such as risk-reducing mastectomy and CPM. Health economic 
participation is vital, for evaluation of emerging technologies and devices, as favourable cost-
effectiveness data will support commissioning of future service provision.      
Translational research 
As acknowledged in the BCC gap analysis4, improved collection of tumour samples and blood from 
patients at all disease stages is essential for the ongoing development of personalised medicine. A 
culture change allowing routine collection and biobanking of samples at diagnosis and during treatment 
is urgently required. Consensus is required to optimise sample collection and preanalytical processing, 
allowing the assessment of fresh and formalin-fixed paraffin embedded samples appropriate for “omics” 
studies as well as techniques such as individualised cell culture analysis, single cell sequencing, and 
patient derived organotypic models and xenografts4.  
Identification and validation of biomarkers which predict for local or “surgical” disease endpoints will be 
critical in the context of developing stratified medicine. Engaging surgeons to routinely participate in 
tissue banking and translational studies is an essential prerequisite for progression of biomarker driven 
research. 
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RESEARCH FUNDING 
As highlighted above, currently only a small proportion of governmental research spend is directed 
towards surgical research. Recent investment in surgical research infrastructure such as the Royal 
College of Surgeons Surgical Trials Initiative which in partnership with the National Institute of Health 
Research (NIHR), the professional associations and charitable funders including Cancer Research UK 
and Breast Cancer Now has created a network of surgical trials units and Surgical Speciality Leads to 
increase the quality and number of surgical trials in the UK.  This drive to place research at the centre 
of surgical culture includes increasing research capacity through developing existing clinical research 
networks, as well as in the training of current and future generations of surgeons in research 
methodology and Good Clinical Practice to ensure the high quality of future studies.  The success of 
this initiative has already been demonstrated with a portfolio of 85 trials recruiting over 25,000 patients 
across 10 different specialites in the four years since inception118. 
Further funding, however, will be needed and funding bodies responsible for supporting surgical and 
breast cancer research in the UK need to be cognisant that addressing  the critical gaps in clinical and 
translation research outlined in this analysis will require significant investment over the next two 
decades to benefit patients, clinicians and healthcare providers. It is anticipated that as surgeons 
continue to embrace ‘team science’ by developing their multidisciplinary collaborations and building 
strong links with methodologists, the funding successes seen in surgically-led studies such as LORIS, 
POSNOC and SMALL will continue increase leading to well-designed and conducted studies that 
address these issues.   
 
CONCLUSIONS 
Surgeons are uniquely placed to design and deliver studies addressing the key gaps in our knowledge 
of breast cancer management. Historically, surgeons have played key roles in improving breast cancer 
outcomes, far beyond evolution of surgical techniques. The concept of ‘surgical’ research being 
restricted to devices or techniques is outdated and should reflect the spectrum of roles that surgeons 
have in contemporary multidisciplinary research.  Evolving research platforms such as ‘window of 
opportunity’ studies and trainee collaboratives offer surgeons unrivalled opportunities to develop more 
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effective treatments, reduce overtreatment, and become involved in research. Open multidisciplinary 
collaboration will be vital to ensure progress in breast cancer research from an international perspective. 
The key research gaps identified in this analysis are summarised in table 1 and include issues 
surrounding overdiagnosis and overtreatment, the selection of patients for neoadjuvant therapies and 
their subsequent surgical management and refining surgical techniques to improve re-operation rates 
in women having breast conserving surgery. Evidence should be generated to enable stratification, 
personalisation (patient selection criteria, the impact of adjuvant treatments and co-morbidities) and 
clinical and cost-effectiveness of breast reconstruction, including mechanisms for the evaluation of 
novel technologies and surgical approaches. Management pathways for the axilla should be further 
clarified particularly in the context of post-neoadjuvant treatment and the indications for risk-reducing 
surgery and contralateral prophylactic mastectomy should be more clearly defined and standardised. 
Proposed strategic solutions to address these gaps include the integration of a research culture into 
surgical practice at all stages of training with breast surgeons becoming key proponents of scientific, 
translational and clinical research and the development of surgical leadership in design and delivery of 
clinical research. Surgical clinician scientists should be nurtured to accelerate translational research to 
address key surgical and clinical questions and an agreed framework for biobanking of clinical samples 
at key points in the patient treatment pathway should be developed to facilitate translational research 
studies. Finally there should be further development and optimisation of clinical trial methodologies 
relevant to address key surgical questions in breast cancer management. 
High-quality research is essential to improve patient outcomes and should be embedded in surgical 
culture to engage and empower surgeons to participate in trials for the benefit of their patients. All 
surgeons should offer their patients the opportunity to enter well-designed trials, and research should 
remain at the heart of breast surgical practice. 
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